PD-L1 GENE SIGNATURE BIOMARKERS OF TUMOR RESPONSE TO PD-1 ANTAGONISTS

摘要

The present disclosure describes PD-L1 gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

主权项

1. A method for testing a tumor for the presence or absence of a biomarker that predicts response to treatment with a PD-1 antagonist, which comprises:
obtaining a sample from the tumor, measuring the raw RNA expression level in the tumor sample for each gene in a PD-L1 gene signature; normalizing each of the measured raw RNA expression levels; and calculating the arithmetic mean of the normalized RNA expression levels for each of the genes to generate a score for the PD-L1 gene signature; wherein the PD-L1 gene signature comprises PD-L1, PD-L2, STAT1, LAG3, CXCL10, and CLEC10a.